{
  "success": true,
  "pagesUsed": [
    4,
    5,
    6,
    10,
    11,
    12,
    15,
    16,
    17,
    18,
    19,
    20
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "To assess the progression-free survival (PFS) of veliparib in combination with carboplatin (C) and paclitaxel (P) compared to placebo with C/P in subjects with a BRCA1 and/or BRCA2 Mutation and HER2-Negative Metastatic or Locally Advanced Unresectable Breast Cancer.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective - Overall Survival",
        "text": "To assess overall survival (OS) in subjects treated with veliparib in combination with C/P versus subjects treated with placebo with C/P.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective - Clinical Benefit Rate",
        "text": "To assess clinical benefit rate (CBR) in subjects treated with veliparib in combination with C/P versus subjects treated with placebo with C/P.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - Objective Response Rate",
        "text": "To assess objective response rate (ORR) in subjects treated with veliparib in combination with C/P versus subjects treated with placebo with C/P.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - PFS2",
        "text": "To assess PFS2 in subjects treated with veliparib in combination with C/P versus subjects treated with placebo with C/P.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Tertiary Objective - Duration of Overall Response",
        "text": "To assess duration of overall response (DOR).",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Tertiary Objective - ECOG Performance Status",
        "text": "To assess change in ECOG performance status.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Tertiary Objective - Quality of Life",
        "text": "To assess change in Quality of Life (QoL).",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Safety Objective",
        "text": "To evaluate the efficacy and tolerability of veliparib in combination with C/P compared to placebo plus C/P.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Progression-free Survival (PFS)",
        "text": "The number of days from the date the subject is randomized to the date the subject experiences disease progression, or to the date of death (all causes of mortality) if disease progression is not reached.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Overall Survival (OS)",
        "text": "The number of days from the day the subject is randomized to the date of the subject's death.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Clinical Benefit Rate (CBR)",
        "text": "The progression-free rate at 24 weeks from the Kaplan-Meier curve for time to progression (defined as from the date of randomization to the date of disease progression).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Objective Response Rate (ORR)",
        "text": "The proportion of subjects with a complete or partial objective response based on RECIST (version 1.1).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "PFS2",
        "text": "The number of days from the day the subject is randomized to the date that the subject has disease progression or death of any cause on the subsequent therapy, whichever occurs first.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Duration of Overall Response (DOR)",
        "text": "Duration of overall response (DOR) evaluated according to progression per RECIST (version 1.1).",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "ECOG Performance Status",
        "text": "Change in ECOG performance status.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Quality of Life (QoL)",
        "text": "Change in Quality of Life (QoL) via the EORTC QLQ-C30/BR23 and EQ-5D-5L questionnaires.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_9",
        "name": "Safety and Tolerability",
        "text": "Study drug exposure, adverse events, serious adverse events, all deaths, as well as changes in laboratory determinations and vital sign parameters.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand (PFS)",
        "populationSummary": "Men and women ≥ 18 years with HER2-negative metastatic or locally advanced unresectable breast cancer and BRCA1/2 germline mutation (ITT population with documented mutations) Summary measure: Hazard Ratio.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Discontinuation of study treatment for reasons other than progression",
            "text": "Subjects who discontinue therapy without progressive disease",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Initiation of subsequent anti-cancer therapy",
            "text": "Subjects who initiate another anti-cancer therapy prior to documented progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Veliparib (120 mg BID Days -2 to 5) + Carboplatin (AUC 6) + Paclitaxel (80 mg/m2) vs Placebo + Carboplatin + Paclitaxel",
        "analysisPopulation": "Men and women ≥ 18 years with HER2-negative metastatic or locally advanced unresectable breast cancer and BRCA1/2 germline mutation (ITT population with documented mutations)",
        "variableOfInterest": "Progression-free survival (PFS) defined as days from randomization to disease progression (RECIST 1.1) or death",
        "summaryMeasure": "Hazard Ratio"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand (OS)",
        "populationSummary": "Men and women ≥ 18 years with HER2-negative metastatic or locally advanced unresectable breast cancer and BRCA1/2 germline mutation Summary measure: Hazard Ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Treatment Crossover",
            "text": "Subjects randomized to placebo crossing over to unblinded veliparib monotherapy after documented progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Veliparib + Carboplatin + Paclitaxel vs Placebo + Carboplatin + Paclitaxel",
        "analysisPopulation": "Men and women ≥ 18 years with HER2-negative metastatic or locally advanced unresectable breast cancer and BRCA1/2 germline mutation",
        "variableOfInterest": "Overall Survival (OS) defined as days from randomization to death from any cause",
        "summaryMeasure": "Hazard Ratio"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand (ORR)",
        "populationSummary": "Subjects with at least one measurable lesion at baseline and documented BRCA mutation Summary measure: Odds Ratio.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_4",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Death prior to tumor assessment",
            "text": "Subject dies before first post-baseline scan",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Veliparib + Carboplatin + Paclitaxel vs Placebo + Carboplatin + Paclitaxel",
        "analysisPopulation": "Subjects with at least one measurable lesion at baseline and documented BRCA mutation",
        "variableOfInterest": "Objective Response Rate (ORR) based on RECIST 1.1",
        "summaryMeasure": "Odds Ratio"
      },
      {
        "id": "est_4",
        "name": "Safety Estimand",
        "populationSummary": "Randomized subjects who received at least one dose of study drug (Safety Population) Summary measure: Risk Difference.",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_9",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment Discontinuation",
            "text": "Discontinuation of study drug due to toxicity",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Veliparib + Carboplatin + Paclitaxel vs Placebo + Carboplatin + Paclitaxel",
        "analysisPopulation": "Randomized subjects who received at least one dose of study drug (Safety Population)",
        "variableOfInterest": "Incidence of adverse events, serious adverse events, and changes in laboratory parameters",
        "summaryMeasure": "Risk Difference"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 5,
      "exploratoryObjectives": 3,
      "totalEndpoints": 9,
      "totalEstimands": 4
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "To assess the progression-free survival (PFS) of veliparib in combination with carboplatin (C) and paclitaxel (P) compared to placebo with C/P in subjects with a BRCA1 and/or BRCA2 Mutation and HER2-Negative Metastatic or Locally Advanced Unresectable Breast Cancer.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective - Overall Survival",
        "text": "To assess overall survival (OS) in subjects treated with veliparib in combination with C/P versus subjects treated with placebo with C/P.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective - Clinical Benefit Rate",
        "text": "To assess clinical benefit rate (CBR) in subjects treated with veliparib in combination with C/P versus subjects treated with placebo with C/P.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - Objective Response Rate",
        "text": "To assess objective response rate (ORR) in subjects treated with veliparib in combination with C/P versus subjects treated with placebo with C/P.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - PFS2",
        "text": "To assess PFS2 in subjects treated with veliparib in combination with C/P versus subjects treated with placebo with C/P.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Tertiary Objective - Duration of Overall Response",
        "text": "To assess duration of overall response (DOR).",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Tertiary Objective - ECOG Performance Status",
        "text": "To assess change in ECOG performance status.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Tertiary Objective - Quality of Life",
        "text": "To assess change in Quality of Life (QoL).",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Safety Objective",
        "text": "To evaluate the efficacy and tolerability of veliparib in combination with C/P compared to placebo plus C/P.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Progression-free Survival (PFS)",
        "text": "The number of days from the date the subject is randomized to the date the subject experiences disease progression, or to the date of death (all causes of mortality) if disease progression is not reached.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Overall Survival (OS)",
        "text": "The number of days from the day the subject is randomized to the date of the subject's death.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Clinical Benefit Rate (CBR)",
        "text": "The progression-free rate at 24 weeks from the Kaplan-Meier curve for time to progression (defined as from the date of randomization to the date of disease progression).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Objective Response Rate (ORR)",
        "text": "The proportion of subjects with a complete or partial objective response based on RECIST (version 1.1).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "PFS2",
        "text": "The number of days from the day the subject is randomized to the date that the subject has disease progression or death of any cause on the subsequent therapy, whichever occurs first.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Duration of Overall Response (DOR)",
        "text": "Duration of overall response (DOR) evaluated according to progression per RECIST (version 1.1).",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "ECOG Performance Status",
        "text": "Change in ECOG performance status.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Quality of Life (QoL)",
        "text": "Change in Quality of Life (QoL) via the EORTC QLQ-C30/BR23 and EQ-5D-5L questionnaires.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_9",
        "name": "Safety and Tolerability",
        "text": "Study drug exposure, adverse events, serious adverse events, all deaths, as well as changes in laboratory determinations and vital sign parameters.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand (PFS)",
        "populationSummary": "Men and women ≥ 18 years with HER2-negative metastatic or locally advanced unresectable breast cancer and BRCA1/2 germline mutation (ITT population with documented mutations) Summary measure: Hazard Ratio.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Discontinuation of study treatment for reasons other than progression",
            "text": "Subjects who discontinue therapy without progressive disease",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Initiation of subsequent anti-cancer therapy",
            "text": "Subjects who initiate another anti-cancer therapy prior to documented progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Veliparib (120 mg BID Days -2 to 5) + Carboplatin (AUC 6) + Paclitaxel (80 mg/m2) vs Placebo + Carboplatin + Paclitaxel",
        "analysisPopulation": "Men and women ≥ 18 years with HER2-negative metastatic or locally advanced unresectable breast cancer and BRCA1/2 germline mutation (ITT population with documented mutations)",
        "variableOfInterest": "Progression-free survival (PFS) defined as days from randomization to disease progression (RECIST 1.1) or death",
        "summaryMeasure": "Hazard Ratio"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand (OS)",
        "populationSummary": "Men and women ≥ 18 years with HER2-negative metastatic or locally advanced unresectable breast cancer and BRCA1/2 germline mutation Summary measure: Hazard Ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Treatment Crossover",
            "text": "Subjects randomized to placebo crossing over to unblinded veliparib monotherapy after documented progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Veliparib + Carboplatin + Paclitaxel vs Placebo + Carboplatin + Paclitaxel",
        "analysisPopulation": "Men and women ≥ 18 years with HER2-negative metastatic or locally advanced unresectable breast cancer and BRCA1/2 germline mutation",
        "variableOfInterest": "Overall Survival (OS) defined as days from randomization to death from any cause",
        "summaryMeasure": "Hazard Ratio"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand (ORR)",
        "populationSummary": "Subjects with at least one measurable lesion at baseline and documented BRCA mutation Summary measure: Odds Ratio.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_4",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Death prior to tumor assessment",
            "text": "Subject dies before first post-baseline scan",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Veliparib + Carboplatin + Paclitaxel vs Placebo + Carboplatin + Paclitaxel",
        "analysisPopulation": "Subjects with at least one measurable lesion at baseline and documented BRCA mutation",
        "variableOfInterest": "Objective Response Rate (ORR) based on RECIST 1.1",
        "summaryMeasure": "Odds Ratio"
      },
      {
        "id": "est_4",
        "name": "Safety Estimand",
        "populationSummary": "Randomized subjects who received at least one dose of study drug (Safety Population) Summary measure: Risk Difference.",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_9",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment Discontinuation",
            "text": "Discontinuation of study drug due to toxicity",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Veliparib + Carboplatin + Paclitaxel vs Placebo + Carboplatin + Paclitaxel",
        "analysisPopulation": "Randomized subjects who received at least one dose of study drug (Safety Population)",
        "variableOfInterest": "Incidence of adverse events, serious adverse events, and changes in laboratory parameters",
        "summaryMeasure": "Risk Difference"
      }
    ]
  }
}